López-Aladid, Ruben
Fernández-Barat, Laia
Alcaraz-Serrano, Victoria
Bueno-Freire, Leticia
Vázquez, Nil
Pastor-Ibáñez, Roque
Palomeque, Andrea
Oscanoa, Patricia
Torres, Antoni
Funding for this research was provided by:
Fondo de Investigaciones Sanitarias (FIS) Instituto de Salud Carlos III (FI19/00090, FIS18-PI18/00145, FIS18-PI18/00145)
CIBER de enfermedades respiratorias – Ciberes ISCIII-FEDER-FSE (CB 06/06/0028/, CB 06/06/0028/)
Article History
Received: 19 September 2022
Accepted: 28 February 2023
First Online: 9 March 2023
Competing interests
: A.Torres has received grants from MedImmune, Cubist, Bayer, Theravance, and Polyphor, together with personal fees as an advisory board member for Bayer, Roche, The Medicines Company, and Curetis. He has received bureau fees for keynote speaker presentations from GSK, Pfizer, AstraZeneca, and the Biotest Advisory Board. These bodies had no connection to the current study. The rest of the authors (RLA, LFB, VAS, LB, NV, RPI, AP and PO) declare no competing interest.